SEVERE ALOPECIA AREATA
Clinical trials for SEVERE ALOPECIA AREATA explained in plain language.
Never miss a new study
Get alerted when new SEVERE ALOPECIA AREATA trials appear
Sign up with your email to follow new studies for SEVERE ALOPECIA AREATA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Hair loss drug litfulo under Real-World watch in 3,000 patients
Disease control Recruiting nowThis study is tracking the safety and effects of the medicine Litfulo in 3,000 adults and teens with severe alopecia areata, a condition causing major hair loss. Participants take the drug as prescribed by their doctor, and researchers monitor side effects and hair regrowth over …
Matched conditions: SEVERE ALOPECIA AREATA
Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
New hope for teens with severe hair loss: Long-Term drug trial launches
Disease control Recruiting nowThis study looks at the long-term safety and effects of the drug ritlecitinib for teenagers with severe alopecia areata, a condition causing major hair loss. Participants must have completed a prior Pfizer study on this drug. All will take ritlecitinib daily for up to 3 years, wi…
Matched conditions: SEVERE ALOPECIA AREATA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
Hair loss hope: daily pill trial for kids with severe alopecia
Disease control Recruiting nowThis study tests a daily pill called ritlecitinib for children aged 6 to 12 with severe alopecia areata, a condition causing significant hair loss. About 225 kids will receive either a high dose, low dose, or placebo for 6 months. The goal is to see if the medicine can safely reg…
Matched conditions: SEVERE ALOPECIA AREATA
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug IBI3013 enters human testing for skin and hair loss conditions
Disease control Recruiting nowThis early-stage study tests a new drug called IBI3013. First, healthy adults receive a single dose to check safety and how the body processes it. Then, people with active vitiligo (white patches on skin) or severe alopecia areata (patchy hair loss) receive multiple doses. The go…
Matched conditions: SEVERE ALOPECIA AREATA
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC